Key Documents

View All Documentation

SML2237

Ormeloxifene

Name: Ormeloxifene
Brand: SIGMA

≥95% (HPLC), SERM modulator, film or powder or oil

Synonym(s):

(trans)-1-[2-[p-(7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy]ethyl]pyrrolidine, 3,4-trans-2,2-Dimethyl-3-phenyl-4-[p-(β-pyrrolidinoethoxy)phenyl]-7-methoxychroman, Centchroman, rel-1-[2-[4-[(3R,4R)-3,4-Dihydro-7-methoxy-2,2-dimethyl-3-phenyl-2H-1-benzopyran-4-yl]phenoxy]ethyl]pyrrolidine, trans-Centchroman

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₃₀H₃₅NO₃

CAS Number:

31477-60-8

Molecular Weight:

457.60

NACRES:

NA.77

UNSPSC Code:

12352200

MDL number:

MFCD05662186

Assay:

≥95% (HPLC)

Form:

film or powder (or oil)

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Ormeloxifene, ≥95% (HPLC)

assay

≥95% (HPLC)

form

film or powder (or oil)

color

colorless to yellow-white

storage temp.

2-8°C

SMILES string

CC([C@@H](C1=CC=CC=C1)[C@@H]2C3=CC=C(OCCN4CCCC4)C=C3)(C)OC5=C2C=CC(OC)=C5

InChI

1S/C30H35NO3/c1-30(2)29(23-9-5-4-6-10-23)28(26-16-15-25(32-3)21-27(26)34-30)22-11-13-24(14-12-22)33-20-19-31-17-7-8-18-31/h4-6,9-16,21,28-29H,7-8,17-20H2,1-3H3/t28-,29+/m1/s1

InChI key

XZEUAXYWNKYKPL-WDYNHAJCSA-N

Description

Biochem/physiol Actions

Ormeloxifene (Centchroman) is a non-steroidal selective estrogen receptor modulator (SERM) that exhibit anticancer activity. Ormeloxifene suppresses the ovariectomy-induced bone resorption in rats.

non-steroidal selective estrogen receptor modulator (SERM)

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ormeloxifene inhibits osteoclast differentiation in parallel to downregulating RANKL-induced ROS generation and suppressing the activation of ERK and JNK in murine RAW264.7 cells.

Geetika Kharkwal et al.

Journal of molecular endocrinology, 48(3), 261-270 (2012-04-12)

Ormeloxifene (Orm), a triphenylethylene compound, has been established as a selective estrogen receptor modulator (SERM) that suppresses the ovariectomy-induced bone resorption in rats. However, the precise mechanism underlying the bone-preserving action of Orm remains unclear. In this study, we evaluated

Assessment of raloxifene, estradiol-17β, dl-ormeloxifene and levormeloxifene on thrombin activity.

William R Surin et al.

Journal of basic and clinical physiology and pharmacology, 1-8 (2014-01-29)

Abstract Background: Cancer is one of the leading causes of morbidity and mortality globally. Cancer-associated thrombosis is well established in clinical settings, and thrombin has been found to induce angiogenesis at cancer sites. This establishes a link between cardiovascular diseases

Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression.

Bilal Bin Hafeez et al.

Molecular cancer therapeutics, 16(10), 2267-2280 (2017-06-16)

Ormeloxifene is a clinically approved selective estrogen receptor modulator, which has also shown excellent anticancer activity, thus it can be an ideal repurposing pharmacophore. Herein, we report therapeutic effects of ormeloxifene on prostate cancer and elucidate a novel molecular mechanism

Global Trade Item Number

SKU	GTIN
SML2237-25MG	04061835494767
SML2237-5MG	04061835494774